Global Endometriosis Treatment Market Size
| Study Period | 2019 - 2029 |
| Market Size (2024) | USD 1.58 Billion |
| Market Size (2029) | USD 2.80 Billion |
| CAGR (2024 - 2029) | 12.07 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
| Market Concentration | Low |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Global Endometriosis Treatment Market Analysis
The Global Endometriosis Treatment Market size is estimated at USD 1.58 billion in 2024, and is expected to reach USD 2.80 billion by 2029, growing at a CAGR of 12.07% during the forecast period (2024-2029).
Endometriosis is the uterine pain that can be life-threatening if not treated properly. The surging burden of endometriosis and disorders like ovarian disorders and menstrual diseases are the major factors projected to drive the endometriosis treatment market. In addition, increased efforts to develop advanced approaches to manage endometriosis and favorable government legislation are supporting market expansion.
According to a March 2023 update by the World Health Organization, approximately 10% (190 million) of women and girls of childbearing age worldwide were affected by endometriosis. The condition is common in females and can start at a person’s first menstrual period and last until menopause. Moreover, according to December 2023 data from Endometriosis UK, the condition is common across the United Kingdom and affects 1 in every 10 women. Thus, the high burden of endometriosis among women is expected to accelerate market growth over the forecast period.
In addition, increasing awareness of the disease and the growing need for early detection are among the major factors driving the market's growth. For instance, Endometriosis Association Inc. is one of the leading non-profit organizations that provides support to women suffering from endometriosis and creates awareness about the condition. Moreover, the organization provides funds and grants to universities and research institutes to discover breakthrough therapies for endometriosis. Thus, such initiatives are anticipated to propel the endometriosis treatment market over the coming years.
Additionally, increased funding and grants from various government and non-government organizations to support endometriosis research are boosting the market’s growth. For instance, in March 2023, researchers at the University of Edinburgh, Aberdeen, and Birmingham received USD 3,00,000 in funding from the Wellbeing of Women and the Scottish government to investigate the efficiency of dichloroacetate in treating endometriosis. In addition, in September 2023, Endometriosis New Zealand granted a research fund to advance the understanding of various treatment approaches to treat endometriosis. This research aimed to investigate various approaches that can be crucial to manage this life-threatening condition. Thus, such funding and grants are anticipated to propel the market’s growth over the forecast period.
Though the abovementioned factors are anticipated to boost the market’s growth over the forecast period, the high cost of endometriosis treatment will likely impede this growth.
Global Endometriosis Treatment Market Trends
The Pain Medication Segment is Expected to Witness Significant Growth Over the Forecast Period
The increasing female population is one of the major factors fueling the demand for pain medications. Endometriosis is associated with painful symptoms such as chronic pelvic pain, dysmenorrhea and dyspareunia, infertility, and psychological suffering. Pain medications can treat the painful symptoms of the disease and reduce its negative impact on quality of life and mental health. For instance, as per the December 2022 data of WebMD LLC, pain medications like nonsteroidal anti-inflammatory drugs and gonadotropin-releasing hormone (GnRH) analogs possess an excellent ability to manage severe pain associated with endometriosis.
The pain medication is cost-effective, safe, and causes very limited side effects. Nonsteroidal anti-inflammatory drugs (NSAIDs) are primarily used in the management of pain caused by endometriosis. Over-the-counter NSAIDs include aspirin, ibuprofen, and naproxen. NSAIDs block the development of prostaglandins, a type of biological compound produced in the body. Elevated prostaglandins cause swelling, pain, and inflammation that many women with endometriosis experience during their periods.
Moreover, strategic collaborations among key players operating in the market are projected to support the market’s growth. For instance, in February 2022, ObsEva SA formed a strategic licensing agreement with Theramex to support the commercialization and market introduction of linzagolix across markets outside the United States, Canada, and Asia. Linzagolix is in the development phase as a potential treatment for endometriosis-associated pain, and ObsEva recently published positive topline results for its first Phase 3 trial (EDELWEISS 3) for this indication.
The increased efforts by market participants and government institutions to develop and commercialize effective pain management options for endometriosis are also projected to propel the segment. For instance, in March 2023, UK researchers received a grant of USD 317,500 to investigate the role of dichloroacetate in pain associated with endometriosis. If approved, it can be an effective treatment option as a non-hormonal treatment for endometriosis. Thus, the increased research efforts to investigate novel pain management therapies for endometriosis are projected to support the segment’s growth over the coming years.
Thus, the increased role of pain management medicines in endometriosis treatment, several collaborations undertaken by market participants, and increased research efforts are anticipated to bolster the segment’s expansion in the coming years.
North America is Expected to Witness Significant Growth Opportunities in the Endometriosis Treatment Market
North America is expected to witness significant growth opportunities over the forecast period due to the availability of technologically advanced products, the rising prevalence of endometriosis in the region, and increasing awareness regarding endometriosis. For instance, according to the January 2024 data from Johns Hopkins University, endometriosis is a common condition across the United States. It affects an estimated 2-10% of American women between the ages of 25 and 40. Thus, the increasing burden of this condition across the region is projected to augment market growth over the coming years.
The new product launches and the presence of key players in the United States are driving the endometriosis treatment market in the country. For instance, in August 2022, the US Food and Drug Administration (FDA) approved Myovant Sciences and Pfizer's MYFEMBREE to manage moderate to severe pain associated with endometriosis in pre-menopausal women. The drug offers a once-daily effective treatment option for the management of pain, with a treatment duration of up to 24 months.
The surging burden of conditions like endometriosis and menstrual disorders across North America and the severe pain associated with these diseases pushed researchers to investigate possible remedies for improving the condition. For instance, in September 2023, researchers from the University of Arizona’s College of Medicine and the Comprehensive Center for Pain and Addiction collaborated to investigate the link between prolactin and endometriosis. This study hopes to bring a lot of findings associated with endometriosis pain and its correlation with different hormones. Thus, such studies are expected to strengthen the understanding of the role of various hormones in endometriosis to develop targeted hormonal therapies, thereby supporting market growth.
Thus, the increasing burden of endometriosis in the region, a surge in research studies for endometriosis, and growing product approvals are projected to support the regional market’s growth over the forecast period.
However, despite the high burden of endometriosis, research funding for this condition is very limited, which is hampering the commercialization and development of new therapeutics. For instance, according to the May 2022 update from the National Institute of Health, the research for endometriosis has been declining, and such instances are projected to hamper market expansion over the coming years.
Global Endometriosis Treatment Industry Overview
The endometriosis treatment market is fragmented in nature due to the presence of several companies operating globally and regionally. Most of the major players focus on R&D to bring innovative products to the market. Some of the major players include Bayer AG, ObsEva, Pfizer Inc., Sun Pharmaceutical Industries Ltd, Cipla, Teva Pharmaceutical Industries Ltd, AstraZeneca, TerSera Therapeutics USA, Tolmar Inc., AbbVie, and Sandoz AG.
Global Endometriosis Treatment Market Leaders
-
Bayer AG
-
Pfizer Inc.
-
AbbVie Inc.
-
Teva Pharmaceutical Industries
-
AstraZeneca
*Disclaimer: Major Players sorted in no particular order
Global Endometriosis Treatment Market News
- May 2023: Abbott announced plans to launch an advanced version of dydrogesterone for the treatment of endometriosis-related pelvic pain. Dydrogesterone has a role in managing pain associated with endometriosis. It is also used to manage irregular cycles and dysfunctional uterine bleeding.
- February 2023: Chugai Pharmaceutical Co. Ltd, Tsukuba Primate Research Center, NIBIOHN, and Jichi Medical University Saitama Medical Center announced the publication of AMY109 in the US scientific journal Science Translational Medicine. AMY109 is being investigated for its role in managing inflammation associated with endometriosis.
Global Endometriosis Treatment Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Driver
4.2.1 Rising Prevalence of Endometriosis
4.2.2 Growing Awareness of the Disease and Rising Need for Early Diagnosis
4.3 Market Restraints
4.3.1 High Cost Associated with the Treatment
4.4 Industry Attractiveness - Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD)
5.1 By Type
5.1.1 Superficial Peritoneal Endometriosis
5.1.2 Endometriomas
5.1.3 Deeply Infiltrating Endometriosis
5.1.4 Other Types
5.2 By Treatment Type
5.2.1 Pain Medication
5.2.2 Hormone Therapy
5.3 By End User
5.3.1 Hospitals
5.3.2 Specialty Clinics
5.3.3 Other End Users
5.4 By Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Bayer AG
6.1.2 Pfizer Inc.
6.1.3 Sun Pharmaceutical Industries Ltd
6.1.4 Cipla Limited
6.1.5 Teva Pharmaceutical Industries Ltd
6.1.6 TerSera Therapeutics USA
6.1.7 Tolmar Inc.
6.1.8 AstraZeneca
6.1.9 ObsEva
6.1.10 AbbVie
6.1.11 Sandoz AG
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Global Endometriosis Treatment Industry Segmentation
As per the scope of the report, endometriosis is a medical condition in which tissues similar to the endometrium grow in ovaries and fallopian tubes. It can affect women of all ages, including teenagers, and cause pain or infertility. The endometriosis treatment market is segmented by type, treatment type, end user, and geography. By type, the market is segmented into superficial peritoneal endometriosis, endometriomas, deeply infiltrating endometriosis, and other types. By treatment type, the market is segmented into pain medication and hormone therapy. By end user, the market is segmented into hospitals, specialty clinics, and other end users. The report also covers the market sizes and forecasts for the endometriosis treatment market in major countries across different regions. For each segment, the market size is provided in terms of value (USD).
| By Type | |
| Superficial Peritoneal Endometriosis | |
| Endometriomas | |
| Deeply Infiltrating Endometriosis | |
| Other Types |
| By Treatment Type | |
| Pain Medication | |
| Hormone Therapy |
| By End User | |
| Hospitals | |
| Specialty Clinics | |
| Other End Users |
| By Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Global Endometriosis Treatment Market Research Faqs
How big is the Global Endometriosis Treatment Market?
The Global Endometriosis Treatment Market size is expected to reach USD 1.58 billion in 2024 and grow at a CAGR of 12.07% to reach USD 2.80 billion by 2029.
What is the current Global Endometriosis Treatment Market size?
In 2024, the Global Endometriosis Treatment Market size is expected to reach USD 1.58 billion.
Who are the key players in Global Endometriosis Treatment Market?
Bayer AG, Pfizer Inc., AbbVie Inc., Teva Pharmaceutical Industries and AstraZeneca are the major companies operating in the Global Endometriosis Treatment Market.
Which is the fastest growing region in Global Endometriosis Treatment Market?
Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Global Endometriosis Treatment Market?
In 2024, the North America accounts for the largest market share in Global Endometriosis Treatment Market.
What years does this Global Endometriosis Treatment Market cover, and what was the market size in 2023?
In 2023, the Global Endometriosis Treatment Market size was estimated at USD 1.39 billion. The report covers the Global Endometriosis Treatment Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Global Endometriosis Treatment Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Global Endometriosis Treatment Industry Report
Statistics for the 2024 Global Endometriosis Treatment market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Global Endometriosis Treatment analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
